Enanta Pharmaceuticals, Inc.
ENTAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company carries a $399.5M market cap, placing it firmly in the small-cap category. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Market Cap
$399.5M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-6.71
EPS (TTM)
$-2.60
EPS (Fwd)
$-2.05
ROE
-59.0%
ROA
-11.8%
Cash
$163.8M
Total Debt
$186.6M
Free CF
$7.7M
52W Change
82.2%
Annual Financials
Cash vs Debt
Enanta Pharmaceuticals, Inc. carries $186.6M in total debt against $163.8M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $7.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -59.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $86.2M (2022) to $65.3M (2025), a 24% decline worth watching.
Investors considering Enanta Pharmaceuticals, Inc. should weigh the typical risks associated with ENTA's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ENTA.